Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EDETATE CALCIUM DISODIUM vs BAFIERTAM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Chelates heavy metals (e.g., lead, cadmium) by forming stable complexes with divalent and trivalent cations, which are then excreted in urine.
BAFIERTAM (monomethyl fumarate) is a prodrug that is rapidly hydrolyzed to monomethyl fumarate, which activates the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway, leading to upregulation of antioxidant response elements and cytoprotective proteins. It also modulates immune responses by shifting from a pro-inflammatory to an anti-inflammatory state.
Treatment of acute and chronic lead poisoning (FDA-approved).,Treatment of poisoning by radioactive metals such as plutonium, americium, and curium (off-label).,Treatment of manganese intoxication (off-label).,Treatment of cadmium poisoning (off-label).
FDA-approved: Treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.,Off-label: None widely documented.
Edetate calcium disodium is administered intravenously or intramuscularly. For lead poisoning: 1000 mg/m²/day IV continuous infusion or in divided doses every 12 hours; alternatively 50 mg/kg/day IV or IM in divided doses every 8-12 hours. Maximum 3000 mg/day. Duration typically 5 days, repeat after 2 days rest. For other heavy metal toxicity: 50 mg/kg/day IV or IM in divided doses every 8-12 hours for 3-5 days.
120 mg orally once daily.
Terminal elimination half-life approximately 1.5-3 hours for the intact chelate; prolonged to 20-40 hours in lead-intoxicated patients due to redistribution of lead from bone.
Approximately 12 hours (range 8–15 hours); permits twice-daily dosing in multiple sclerosis.
Not metabolized; excreted unchanged in urine, primarily via glomerular filtration.
BAFIERTAM is a prodrug that is rapidly metabolized by esterases in the gastrointestinal tract, blood, and tissues to monomethyl fumarate. Monomethyl fumarate is further metabolized via the tricarboxylic acid (TCA) cycle, with no significant involvement of cytochrome P450 enzymes.
Primarily renal (90-100% as chelated lead complex within 24-48 hours); minimal biliary/fecal excretion (<5%).
Primarily via renal excretion as unchanged drug (approximately 80% of the dose); minimal biliary/fecal elimination (<5%).
Negligible (<5%); primarily binds lead in extracellular fluid.
30–40% bound to plasma proteins, primarily albumin.
0.3-0.5 L/kg (confined mainly to extracellular space; does not penetrate cells or CNS).
Approximately 0.5–0.7 L/kg; indicates distribution into total body water with limited tissue binding.
IV or IM: 100% (not absorbed orally).
Oral: Approximately 50% (due to first-pass metabolism); administer with food to reduce GI irritation.
GFR > 50 m L/min: no adjustment. GFR 30-50 m L/min: reduce dose by 50%. GFR 15-29 m L/min: reduce dose by 75%. GFR < 15 m L/min or dialysis: contraindicated or use with extreme caution at 10-20% of normal dose with monitoring.
No dose adjustment required for GFR ≥30 m L/min. Not recommended for GFR <30 m L/min.
No specific guidelines for Child-Pugh based modifications. Use with caution in severe hepatic impairment due to potential for electrolyte disturbances and nephrotoxicity.
Use with caution in hepatic impairment; reduce dose to 60 mg once daily in Child-Pugh Class B or C.
For lead poisoning: 1000 mg/m²/day IV continuous infusion or in divided doses every 12 hours; or 50 mg/kg/day IV or IM in divided doses every 8-12 hours. Maximum 3000 mg/day. Course: 5 days, may repeat after 2 days rest. For other indications: weight-based dosing similar to adults (50 mg/kg/day).
Not established in pediatric patients.
Start at low end of dosing range (e.g., 30-40 mg/kg/day) due to age-related decreased renal function. Monitor renal function and electrolytes closely. Avoid use in patients with pre-existing renal impairment without dose reduction.
No specific dose adjustment; use with caution due to age-related decline in renal function.
Black box warning for nephrotoxicity, particularly at high doses; may cause fatal renal failure. Avoid in patients with renal disease unless benefits outweigh risks. Monitor renal function closely during therapy.
No black box warning.
Nephrotoxicity - monitor BUN, creatinine, and urinalysis at baseline and during therapy.,Neurotoxicity - may cause tremors, myoclonus, and seizures, especially with high doses.,Hepatotoxicity - monitor liver function tests.,Arrhythmias - may cause QT prolongation; monitor ECG.,Hypocalcemia - monitor serum calcium levels; may cause tetany.,Use with caution in patients with asthma or allergic history.,Not recommended for prophylaxis of heavy metal poisoning.
Lymphopenia: May cause reduction in lymphocyte counts; monitor complete blood count before and periodically during treatment.,Hypersensitivity reactions: Anaphylaxis and angioedema may occur; discontinue if severe.,Progressive multifocal leukoencephalopathy (PML): Reported in patients with prolonged lymphopenia; consider holding therapy if lymphocyte counts drop below 0.2 x 10^9/L.,Hepatic injury: Elevations of liver enzymes have been reported; monitor in patients with pre-existing liver disease.,Flushing and gastrointestinal events: Common; may be managed by taking with food or using aspirin.
Severe renal disease or anuria.,Acute pancreatitis.,Known hypersensitivity to edetate calcium disodium or any component.,Concurrent use with other nephrotoxic drugs.,Pregnancy (only if clearly needed due to risk to fetus from metal poisoning).
Known hypersensitivity to BAFIERTAM, monomethyl fumarate, or any excipient.,Concomitant use with dimethyl fumarate or other fumaric acid esters.
No specific food restrictions, but maintain adequate hydration. Avoid alcohol due to potential renal effects.
Administer with food to reduce flushing and gastrointestinal adverse effects. Avoid alcohol consumption during treatment as it may exacerbate flushing. No specific dietary restrictions are required.
FDA Pregnancy Category C. In animal studies, edetate calcium disodium has been shown to be teratogenic (skeletal anomalies) at doses approximately 0.25 times the human dose. There are no adequate and well-controlled studies in pregnant women. The drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. First trimester: Risk cannot be ruled out; potential for teratogenic effects. Second and third trimesters: Potential fetal toxicity from chelation of essential minerals; avoid use unless necessary.
BAFIERTAM (monomethyl fumarate) is contraindicated in pregnancy. Animal studies show malformations at subclinical doses. No human data; avoid in all trimesters due to teratogenic potential.
It is not known whether edetate calcium disodium is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. No M/P ratio has been reported.
No data on presence in human milk. M/P ratio unknown. Risk of infant exposure cannot be excluded. Discontinue breastfeeding or drug, considering importance to mother.
Physiologic increases in renal blood flow and glomerular filtration rate during pregnancy may increase clearance of edetate calcium disodium. Pharmacokinetic data are lacking, but dose adjustments may not be required as dosing is typically based on lead levels and renal function. However, careful monitoring of lead levels and renal function is essential. The drug is contraindicated in patients with severe renal impairment.
No dose adjustment data; contraindicated in pregnancy. If unintentional exposure occurs, discontinue immediately. Pharmacokinetic changes unknown but drug should not be used.
Edetate calcium disodium is used for chelation therapy in heavy metal poisoning, particularly lead. Monitor renal function closely due to risk of nephrotoxicity. Administer via slow IV infusion (over 8-12 hours) after dilution to minimize irritation. Contraindicated in anuria or severe renal impairment. Rapid infusion may cause hypocalcemic tetany; ensure adequate hydration to enhance lead excretion. Use with caution in patients with arrhythmias due to potential electrolyte disturbances.
BAFIERTAM (monomethyl fumarate) is a prodrug of monomethyl fumarate, indicated for relapsing forms of multiple sclerosis. Administer with food to reduce flushing and gastrointestinal adverse effects. Titrate as per recommended schedule to improve tolerability. Monitor complete blood count, liver function tests, and renal function at baseline and periodically. Flushing may be reduced by taking with food or using non-enteric coated aspirin (325 mg) 30 minutes prior. Avoid concurrent use with dimethyl fumarate or other fumaric acid esters.
This medication is used to remove lead from your body.,You will receive this drug as an intravenous infusion over several hours.,Drink plenty of fluids during treatment to help flush out lead.,Report any muscle cramps, numbness, or tingling immediately.,Your kidney function and electrolyte levels will be monitored during treatment.,Avoid taking other medications without consulting your doctor, especially those affecting the kidneys.
Take BAFIERTAM exactly as prescribed, usually twice daily with food.,Flushing and gastrointestinal upset are common but may decrease over time; taking with food and gradual dose titration helps.,Do not crush, chew, or open capsules; swallow whole.,Report any signs of infection, unusual bruising or bleeding, or severe abdominal pain to your healthcare provider.,Avoid consuming alcohol, as it may increase flushing risk.,If you miss a dose, take it as soon as you remember unless it is near the time of the next dose; do not double up.,Inform all healthcare providers that you are taking BAFIERTAM.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EDETATE CALCIUM DISODIUM vs BAFIERTAM, answered by our medical review team.
EDETATE CALCIUM DISODIUM is a Chelating Agent that works by Chelates heavy metals (e.g., lead, cadmium) by forming stable complexes with divalent and trivalent cations, which are then excreted in urine.. BAFIERTAM is a Iron Chelating Agent that works by BAFIERTAM (monomethyl fumarate) is a prodrug that is rapidly hydrolyzed to monomethyl fumarate, which activates the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway, leading to upregulation of antioxidant response elements and cytoprotective proteins. It also modulates immune responses by shifting from a pro-inflammatory to an anti-inflammatory state.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EDETATE CALCIUM DISODIUM and BAFIERTAM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EDETATE CALCIUM DISODIUM is: Edetate calcium disodium is administered intravenously or intramuscularly. For lead poisoning: 1000 mg/m²/day IV continuous infusion or in divided doses every 12 hours; alternatively 50 mg/kg/day IV or IM in divided doses every 8-12 hours. Maximum 3000 mg/day. Duration typically 5 days, repeat after 2 days rest. For other heavy metal toxicity: 50 mg/kg/day IV or IM in divided doses every 8-12 hours for 3-5 days.. The standard adult dose of BAFIERTAM is: 120 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EDETATE CALCIUM DISODIUM and BAFIERTAM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EDETATE CALCIUM DISODIUM is classified as Category C. FDA Pregnancy Category C. In animal studies, edetate calcium disodium has been shown to be teratogenic (skeletal anomalies) at doses approximately 0.25 times the human dose. There . BAFIERTAM is classified as Category C. BAFIERTAM (monomethyl fumarate) is contraindicated in pregnancy. Animal studies show malformations at subclinical doses. No human data; avoid in all trimesters due to teratogenic p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.